TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer... (ollaborationwith Rudolph Tanzi Ph.D. sci...)

TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease

Date:9/25/2007

ollaboration with Rudolph Tanzi, Ph.D., scientific co-founder of TorreyPines and Director of the Genetics and Aging Research Unit at the Massachusetts General Institute for Neurodegenerative Disorders (MIND).

"The collaboration with Eisai has been very successful and one which I believe has the potential to yield valuable new genetic targets for drug discovery aimed at Alzheimer's disease," said Dr. Tanzi.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for the identification of genes associated with Alzheimer's disease, the biological validation of genetic targets, and the possible discovery of therapies to treat Alzheimer's disease. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. In particular there is no guarantee that TorreyPines will be successful in the identification or validation of genes associated with Alzheimer's disease or the discovery of therapies to treat Alzheimer's disease, t
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Extended data analysis using DeCyder EDA
3. Detection of N-in-1 Experiments: Extending the Range of N Using the API 3000 LC/MS/MS System
4. Techware to extend broadband wireless network to Butler
5. UW gets $5M to extend entrepreneurship
6. Creativity, innovation extend to municipalities
7. NimbleGen extends research market reach
8. TomoTherapy extends reach to Germany
9. Third Wave says patent extends IP reach
10. `Single-sales factor extends tax treatment to tech, service firms
11. Alumni Association extends database help to university

Post Your Comments:

TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer...(ollaborationwith Rudolph Tanzi Ph.D. sci...)